A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
收藏DataCite Commons2025-06-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011273/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
1. To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 milligram per day (mg/d) compared with placebo in prevention of relapse in patients with schizophrenia2. To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
提供机构：
Vivli
创建时间：
2025-04-04
